Navigation Links
OxThera Raises Capital for Further Clinical Development of Oxabact(R)
Date:9/19/2012

STOCKHOLM, September 19, 2012 /PRNewswire/ --

OxThera AB has successfully raised MSEK 39 in a rights issue. The proceeds from the financing will enable OxThera to complete a new clinical study to confirm the positive effects of treatment with Oxabact® previously seen in patients with Primary Hyperoxaluria, a debilitating medical condition for which there is no effective treatment today.

"We appreciate the continued support from our shareholders, including HealthCap, Industrifonden and Q-Med[1], as well as their strong belief in Oxabact®", says Elisabeth Lindner, CEO of OxThera. "Our mapping of OxThera's previous scientific and clinical findings has resulted in an improved medical product that will support a regulatory filing for a confirmatory clinical trial later this year." Elisabeth Lindner continues.

OxThera holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria. Oxabact® is an oral product composed of highly concentrated freeze-dried live bacteria (Oxalobacter formigenes), administered in capsules. The drug is designed for delivery in the lower part of the small intestine, where enteric elimination of endogenous oxalate is initiated. OxThera is currently discussing a complete Oxabact® clinical development plan with regulatory agencies in the EU and in the US for the treatment of patients suffering from Primary Hyperoxaluria.

About primary hyperoxaluria

Primary hyperoxaluriais a rare inborn autosomal genetic disorder leading to markedly elevated levels of endogenous oxalate in plasma and urine. High levels of urinary oxalate cause kidney damage, including kidney stone formation and/or calcification of the kidney. If left untreated, the disease can cause kidney failure and premature death. There is a high medical need for effective treatments of Primary Hyperoxaluria. Currently, the only available cure is a combined liver and kidney transplantation.

OxThera estimates that there are about 2,000 patients with Primary Hyperoxaluria in the Western world. Oxabact® holds orphan drug designations in the EU and the US for the treatment of primary hyperoxaluria.

About OxThera

OxThera holds worldwide rights for compositions and methods of use for treatment of hyperoxaluria. OxThera currently has two products in its pipeline: Oxabact® for the treatment of primary hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria.

For further information, please contact: Elisabeth Lindner, CEO of OxThera AB, Phone +46-8-660 0223

http://www.oxthera.com

--------------------------------------------------

1. A division of Galderma.


'/>"/>
SOURCE OxThera
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
4. Cerecor Raises $22 Million Series A Financing
5. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
6. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
7. Juventas Therapeutics Raises $22.2 Million Series B Financing
8. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
9. Safeway Raises Over $9 Million to Fund Prostate Cancer Research
10. MiMedx Group Raises over $4.9 Million through the Exercise of Callable Warrants
11. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2016)... ... May 18, 2016 , ... Tech Coast Angels ... Award to Cognition Therapeutics at the annual ACA Summit last week in Philadelphia. ... by one of ACA’s member angel groups. It is the highest honor available for ...
(Date:5/18/2016)... ... 18, 2016 , ... Every day, more than 5,400 ER ... Costing more than $56 billion in direct costs annually, asthma remains a critical ... the suffering associated with uncontrolled asthma can be overwhelmingly disproportionate and better managed,” ...
(Date:5/17/2016)... ... May 17, 2016 , ... ... animal waste reduction applications, announced today it will be showcasing ManureMagic™ at booth ... ManureMagic™ was featured in the Wall Street Journal last year and more recently ...
(Date:5/17/2016)... , May 17, 2016 ... located in Basel, Switzerland ... oral inhibitor of P38 mitogen-activated protein kinase. ... Strekin will build the necessary research ... indications in which MAP Kinases play fundamental roles. ...
Breaking Biology Technology:
(Date:3/18/2016)... 18, 2016 --> ... ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance ... in the border security market and the continuing migration crisis ... Europe has led visiongain to publish this ... --> defence & security companies in the ...
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... ) - --> - Renvoi : image ... --> --> ... biométriques, fournit de nouveaux lecteurs d,empreintes digitales pour ... de DERMALOG sera utilisé pour produire des cartes ...
(Date:3/9/2016)... -- This BCC Research report provides an overview of ... (RNA Seq) market for the years 2015, 2016 and ... data analysis, and services. Use this report ... such as RNA-Sequencing tools and reagents, RNA-Sequencing data analysis, ... segment and forecast their market growth, future trends and ...
Breaking Biology News(10 mins):